Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

- PMLiVE

Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

Join this live webinar focusing on patient recruitment and retention in rare disease trials.

Innovative Trials

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bn

The agreement builds on the companies’ peptide-drug conjugate collaboration announced in 2019

- PMLiVE

Merck’s adult-specific pneumococcal vaccine shows promise in late-stage study

There are more than 100 types of pneumococcal bacteria, which can affect adults differently than children

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

FDA establishes new CDER centre focused on promoting clinical trial innovation

The C3TI will give internal and external parties easier access to information on clinical trial innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links